Precision medicine strategies that actually reach patients
MojoBioMD helps laboratories, diagnostics and biopharma companies turn complex science into practical strategies for patient identification, diagnostic adoption, market access, partnerships, and global commercialization.

DIAGNOSTIC AND COMMERCIAL STRATEGY

Building an actionable path from scientific discovery to clinical adoption. This includes market assessment, product strategy, target product profiles, launch planning, and commercialization recommendtions

Led by Molly Martell, MSc.

Molly Martell is a global diagnostics and precision medicine leader with more than 15 years of experience connecting scientific innovation with the systems required for patient impact.

Her work spans companion diagnostics, molecular testing, NGS and liquid biopsy, market access, reimbursement, strategic partnerships, and global commercialization.

She has led collaborations with diagnostic developers, international laboratories, biopharma organizations, and healthcare stakeholders to improve testing availability and adoption.

MojoBioMD supports organizations at critical points in the diagnostic lifecycle—from early opportunity assessment and partnership strategy through launch, access, and international expansion.

PATIENT IDENTIFICATION AND ACCESS

Address any and all barriers that can prevent patients from receiving appropriate testing through diagnostic pathway, evidence, reimbursement, laboratory readiness, and adoption strategies.

PARTNERSHIPS AND GLOBAL EXPANSION

Develop laboratory, diagnostic, and biopharma partnerships to deliver testing at scale. MojoBioMD brings experience across the United States and international markets, including Australia, Brazil, China, India, Japan, and Europe.